🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the...

ir.revmed.com
20
232
38
731
258,608
Absolutely awesome to hear🔥

Apr 13, 2026 · 4:40 PM UTC

735